Lyell Immunopharma, Inc.LYELNASDAQ
LOADING
|||
| Metric | Dec 20 | Dec 21 | Dec 22 | Dec 23 | Dec 24 |
|---|---|---|---|---|---|
| Revenue | 8 | 11↑37.3% | 85↑695.1% | 0↓99.8% | 0↓53.1% |
| Gross Profit | 8 | 11↑37.3% | 85↑695.1% | 0↓99.8% | 0↓53.1% |
| Operating Income | -212 | -215↓1.3% | -187↑12.9% | -247↓32.0% | -359↓45.2% |
| Net Income | -204 | -250↓22.4% | -183↑26.8% | -235↓28.1% | -343↓46.2% |
| EBITDA | -215 | -201↑6.6% | -169↑16.0% | -227↓34.1% | -201↑11.5% |
| EPS Diluted | -0.84 | -1.03↓22.2% | -0.74↑28.1% | -0.93↓26.1% | -1.31↓40.1% |